MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer

International Journal of Cancer

Volumn 89, Issue 3, 2000, Pages 265-270

  Ko, Jiunn Liang ^a   Cheng, Ya Wen ^a   Chang, Shu Lin ^a   Su, Jen Ming ^a   Chen, Chih Yi ^b   Lee, Huei ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN MDM2;

ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; EXONS; FEMALE; GENE DELETION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033946522     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000520)89:3<265::AID-IJC9>3.0.CO;2-N     Document Type: Article

References (25)

1. BATE, S., PHILLIPS, A.C., CLARK, P.A., STOTT, F., LUDWIG, R.L. and VOUSDEN, K.H., p14 ARF links the tumor suppressors RB and p53. Nature (Lond.), 395, 124-126 (1998).
2. BROWN, D.R., THOMAS, C.A. and DEB, S.P., The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J., 17, 2513-2525 (1998).
3. CARROLL, P.E., OKUDA, M., HORN, H.F., BIDDINGER, P., STAMBROOK, P.J., GLEICH, L.L., LI, Y.Q., TARAPORE, P. and FUKASAWA, K., Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/ or mdm2 overexpression. Oncogene, 18, 1935-1944 (1999).
4. FAKHARZADEH, S.S., TRUSKO, S.P. and GEORGE, D.L., Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 10, 1565-1568 (1991).
5. FOULKES, W. D., STAMP, G.W.H., AFZAL, N., MCFARLANE, C.P., TROWSDALE, L. and CAMPBELL, I.G., MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Brit. J. Cancer, 67, 551-559 (1995).
6. GORGOULIS, V.G., ZACHARATOS, P.V., MANOLIS, E., IKONOMOPOULOS, J.A., DAMALAS, A., LAMPRINOPOULOS, C., RASSIDAKIS, G.Z., ZOUMPOURLIS, V., KOTSINAS, A., RASSIDAKIS, A.N., HALAZONETIS, T.D. and KITTAS, C., Effects of p53 mutants derived from lung carcinomas on the p53 responsive element (p53RE) of the MDM2 gene. Brit. J. Cancer, 77, 374-384 (1998).
7. GORGOULIS, V.G., ZOUMPOURLIS, V., RASSIDAKIS, G.Z., KARAMERIS, A., RASSIDAKIS, A.N., SPANDIDOS, D.A. and KITTAS, C., A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J. Pathol., 180, 129-137 (1996).
8. HIGASHIYAMA, M., DOI, O., KODAMA, K., YOKOUCHI, H., KASIGAI, T., ISHIGURO, S., TAKAMI, K., NAKAYAMA, T.M. and NISHISHO, I., MDM2 gene amplification and expression in non small cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Brit. J. Cancer, 75, 1302-1308 (1997).
9. IGGO, R., GATTER, K., BARTEK, J., LANE, D. and HARRIS, A.L., Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 335, 675-679 (1990).
10. LAMB, P. and CRAWFORD, L., Characterization of the human p53 gene. Mol. cell. Biol., 6, 1379-1385 (1986).
11. LANDERS, J.E., CASSEL, S.L. and GEORGE, D.L., Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res., 57, 3562-3568 (1997).
12. LEVESQUE, M., D'COSTA, M., SPRATT, E.H., YAMAN, M.M. and DIAMANDIS, P., Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. Int. J. Cancer, 79, 494-501 (1998).
13. MOMAND, J., JUNG, D., WILCZYNSKI, S. and NILAND, J., The MDM2 gene amplification database. Nucl. Acids Res., 26, 3453-3459 (1998).
14. MOMAND, J., ZAMBETTI, G.P., OLSON, D.C., GEORGE, D. and LEVINE, A.J., The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell, 69, 1237-1245 (1992).
15. OLINER, J.D., PIETENPOL, J.A., THIAGALINGAM, S., GVURIS, J., KINZLER, K.W. and VOGELSTEIN, B., Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature (Lond.), 362, 857-860 (1993).
16. OLSON, D.C., MARECHAL, V., MOMAND, J., CHEN, J., ROMOCKI, C. and LEVINE, A.J. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene, 8, 2353-2360 (1993).
17. SIGALAS, I., CALVERT, A.H., ANDERSON, J.J., NEAL, D.E. and LUNEC, J., Alternative spliced MDM2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature (Med.), 2, 912-917 (1996).
18. TANNER, B., HENGSTLER, J.G., LAUBSCHER, S., MEINERT, R., OESCH, F., WEIKEL, W., KNAPSTEIN, P.G. and BECKER, R., MDM2 mRNA expression is associated with survival in ovarian cancer. Int. J. Cancer, 74, 438-442 (1997).
19. TOMIZAWA, Y., KOHNO, T., FUJITA, T., KIYAMA, M., SAITO, R., NOGUCHI, M., MATSUNO, Y., HIROHASHI, S., YAMAGUCHI, N., NAKAJIMA, T. and YOKOTA, J., Correlation between the status of the p53 gene and survival in patients with stage 1 non small cell lung carcinoma. Oncogene, 18, 1007-1014 (1999).
20. VOGELSTEIN, B. and KINZLER, K.W., p53 function and dysfunction. Cell, 70, 523-526 (1992).
21. WANG, X., CHRISTIANI, D.C., MARK, E.J., NELSON, H., WIENCKE, J.K., GUNN, L., WAIN, J.C. and KELSEY, K.T., Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma. Cancer, 85, 1734-1739 (1999).
22. WANG, Y.C., CHEN, C.Y., CHEN, C.K., CHERNG, S.H., HO, W.L. and LEE, H., High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Cancer Res., 58, 328-333 (1998).
23. WORLD HEALTH ORGANIZATION, Histological typing of lung tumors (2nd ed.), WHO, Geneva (1981).
24. WU, X., KEMP, B., AMOS, C.I., HONN, S.E., ZHANG, W., WALSH, G.L. and SPITZ, M.R., Associations among telomerase activity, p53 protein overexpression, and genetic instability in lung cancer. Brit. J. Cancer, 80, 453-457 (1999).
25. ZAUBERMAN, A., FIUSBERG, D., HAUPT, Y., BARAK, Y. and OREN, M., A functional p53-responsive intronic promoter is contained within the human MDM2 gene. Nucl. Acids Res., 23, 2584-2592 (1995).